CMTM3 and CMTM5, which have 42% homology and contain a typical CpG island, generally tend to be regarded as tumor suppressors because of their low expression in gastric cancer, prostate cancer, and HCC [20–23]. This evidence concerns the gene CMTM5 and prostate cancer.